These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 36567441)

  • 41. Phase II trial of postoperative adjuvant intraperitoneal cisplatin and fluorouracil and systemic fluorouracil chemotherapy in patients with resected gastric cancer.
    Atiq OT; Kelsen DP; Shiu MH; Saltz L; Tong W; Niedzwiecki D; Trochanowski B; Lin S; Toomasi F; Brennan M
    J Clin Oncol; 1993 Mar; 11(3):425-33. PubMed ID: 8445416
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer.
    Honecker F; Kollmannsberger C; Quietzsch D; Haag C; Schroeder M; Spott C; Hartmann JT; Baronius W; Hempel V; Kanz L; Bokemeyer C
    Anticancer Drugs; 2002 Jun; 13(5):497-503. PubMed ID: 12045461
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer.
    Kim DY; Kim JH; Lee SH; Kim TY; Heo DS; Bang YJ; Kim NK
    Ann Oncol; 2003 Mar; 14(3):383-7. PubMed ID: 12598342
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phase II study of the modified regimen of etoposide, leucovorin and 5-fluorouracil for patients with advanced gastric cancer.
    Chiou TJ; Tung SL; Hsieh RK; Wang WS; Yen CC; Fan FS; Liu JH; Chen PM
    Jpn J Clin Oncol; 1998 May; 28(5):318-22. PubMed ID: 9703859
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sequence-dependence of cisplatin and 5-fluorouracil in advanced and recurrent gastric cancer.
    Koizumi W; Kurihara M; Hasegawa K; Chonan A; Kubo Y; Maekawa R; Iwasaki R; Sasai T; Fukuyama Y; Ishikawa K; Miyoshi K; Yasutake K; Hayakawa M
    Oncol Rep; 2004 Sep; 12(3):557-61. PubMed ID: 15289837
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment of advanced colorectal and gastric cancer with cisplatinum and 5-fluorouracil. A pilot study.
    Zaniboni A; Zambruni A; Marpicati P; Gorni F; Simoncini E; Ragni F; Marini G
    Chemioterapia; 1986 Oct; 5(5):347-50. PubMed ID: 3791483
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Evaluation of the efficacy and toxicity of protocol cisplatin, 5-fluorouracil, leucovorin compared to protocol fluorouracil, doxorubicin and mitomycin C in locally advanced and metastatic gastric cancer].
    Andrić Z; Randjelović T; Kovčin V; Gutović J; Crevar S; Murtezani Z; Kostić S
    Srp Arh Celok Lek; 2012; 140(5-6):305-12. PubMed ID: 22826983
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [5-Fluorouracil concentration in various tissues from cancer patients after oral administration of 5-fluorouracil].
    Nakamura T; Hashimoto I; Sawada Y; Mikami J; Yoshimoto M; Nishidai H; Nakanishi Y; Kashi Y
    Gan To Kagaku Ryoho; 1984 May; 11(5):1037-48. PubMed ID: 6721512
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A phase III trial comparing oral S-1/cisplatin and intravenous 5-fluorouracil/cisplatin in patients with untreated diffuse gastric cancer.
    Ajani JA; Abramov M; Bondarenko I; Shparyk Y; Gorbunova V; Hontsa A; Otchenash N; Alsina M; Lazarev S; Feliu J; Elme A; Esko V; Abdalla K; Verma U; Benedetti F; Aoyama T; Mizuguchi H; Makris L; Rosati G;
    Ann Oncol; 2017 Sep; 28(9):2142-2148. PubMed ID: 28911091
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [A case of advanced gastric cancer with carcinomatosa peritonitis effectively treated by 5-FU and low-dose CDDP therapy].
    Saito E; Kunii Y; Wada G; Tsuchiya S; Yamasaki T; Sakakibara N
    Gan To Kagaku Ryoho; 1997 Jul; 24(9):1153-6. PubMed ID: 9239170
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid.
    Machover D; Goldschmidt E; Chollet P; Metzger G; Zittoun J; Marquet J; Vandenbulcke JM; Misset JL; Schwarzenberg L; Fourtillan JB
    J Clin Oncol; 1986 May; 4(5):685-96. PubMed ID: 3517242
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase I dose-escalating study of 24-h continuous infusion of 5-fluorouracil in combination with weekly docetaxel and cisplatin in patients with advanced gastric cancer.
    Wang B; Zhang W; Hong X; Guo Y; Li J
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):213-8. PubMed ID: 18343924
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase II study of oxaliplatin in combination with continuous infusion of 5-fluorouracil/leucovorin as first-line chemotherapy in patients with advanced gastric cancer.
    Hwang WS; Chao TY; Lin SF; Chung CY; Chiu CF; Chang YF; Chen PM; Chiou TJ
    Anticancer Drugs; 2008 Mar; 19(3):283-8. PubMed ID: 18510174
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A phase II study of irinotecan with biweekly, low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as first line therapy for patients with recurrent or metastatic gastric cancer.
    Kim BG; Oh SY; Kwon HC; Lee S; Lee DM; Kim SG; Kim DK; Jang JS; Kim MC; Kim SH; Kim HJ
    Am J Clin Oncol; 2010 Jun; 33(3):246-50. PubMed ID: 19770628
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparative analysis of the efficacy and safety of oxaliplatin plus 5-fluorouracil/leucovorin (modified FOLFOX6) with advanced gastric cancer patients having a good or poor performance status.
    Hacibekiroglu I; Kodaz H; Erdogan B; Turkmen E; Esenkaya A; Uzunoglu S; Cicin I
    Asian Pac J Cancer Prev; 2015; 16(6):2355-9. PubMed ID: 25824764
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Biweekly regimen of high dose of leucovorin, 5-fluorouracil, and paclitaxel for patients with advanced gastric cancer].
    Feng JF; Lu JW; Sun XF
    Ai Zheng; 2004 Dec; 23(12):1704-6. PubMed ID: 15601565
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A multicentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer.
    Tebbutt NC; Norman A; Cunningham D; Iveson T; Seymour M; Hickish T; Harper P; Maisey N; Mochlinski K; Prior Y; Hill M
    Ann Oncol; 2002 Oct; 13(10):1568-75. PubMed ID: 12377644
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment of advanced oesophagogastric cancer with FOLFOX-4 regimen followed by leucovorin/bolus and continuous infusion 5-FU as maintenance chemotherapy in patients aged ≥ 75 years with impaired performance status.
    Petrioli R; Francini E; Roviello F; Marrelli D; Miano ST; Fiaschi AI; Laera L; Bellini MA; Roviello G
    J Geriatr Oncol; 2015 Sep; 6(5):380-6. PubMed ID: 26228711
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intermittent FLDP: 24-h infusion of 5-FU on days 1, 3 and 5 combined with low-dose cisplatin on days 1-5 for gastric cancer, and its pharmacologic and kinetic rationale.
    Terashima M; Irinoda T; Kawamura H; Takagane A; Abe K; Oyama K; Fujiwara H; Saito K; Gotoh M; Shirasaka T
    Cancer Chemother Pharmacol; 2003 Mar; 51(3):240-6. PubMed ID: 12655443
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Significant Role of Cyclin D1 in the Synergistic Growth-inhibitory Effect of Combined Therapy of Vandetanib with 5-Fluorouracil for Gastric Cancer.
    Yawata K; Osada S; Tanahashi T; Matsui S; Sasaki Y; Tanaka Y; Okumura N; Matsuhashi N; Takahashi T; Yamaguchi K; Yoshida K
    Anticancer Res; 2016 Oct; 36(10):5215-5226. PubMed ID: 27798882
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.